Biluron

Quick links to important sections

Biluron

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biluron

Property Description
Active ingredient Bicalutamide (INN)
Form Oral Tablet
Pharmacological class Nonsteroidal Antiandrogen (NSAA)
Common use Management of androgen-sensitive conditions
Origin Synthetic compound (Anilide derivative)

What Type of Medicine is Biluron (Bicalutamide)?

Biluron is a specialized, prescription-only pharmaceutical agent classified within the Nonsteroidal Antiandrogen (NSAA) pharmacological group. Its active compound, Bicalutamide (INN), is a synthetic anilide derivative characterized as a key hormonal therapy agent. This drug is defined by its mechanism as a pure anti-androgen, meaning its primary function is strictly focused on blocking specific hormone receptors, a characteristic essential for managing physiological processes driven by androgen signaling.

Composition and Pharmaceutical Form

The medicine is manufactured for systemic delivery in the form of tablets, intended for consistent oral administration. The Bicalutamide within the tablets exists chemically as a racemic mixture, a feature common to many synthetic drugs. The therapeutic activity is concentrated in the (R)-enantiomer, which offers a longer duration of effect than its non-active counterpart. Biluron is a single-ingredient product, containing only Bicalutamide along with the solid pharmaceutical excipients required for the final tablet structure, a characteristic that simplifies the formulation profile.

General Purpose: Androgen Receptor Blockade

The general purpose of Biluron is to strategically counteract the influence of male sex hormones, or androgens, on target cells. This action is accomplished through competitive inhibition at the Androgen Receptor (AR) site. The Bicalutamide occupies the receptor, thereby physically blocking the binding and stimulatory effects of natural androgens like testosterone. This targeted intervention is relied upon to cause a functional growth arrest within hormone-sensitive cells. Its typical neutral use scenario involves being prescribed to adult male patients as part of a long-term strategy for managing conditions driven by excessive androgen stimulation.

What side effects are possible with Biluron?

Possible Side Effects and Safety Information

The safety profile of Biluron (Bicalutamide) is officially categorized by the frequency and organ systems affected, as documented in regulatory prescribing information. The adverse reactions are primarily grouped into Very Common, Common, Uncommon, and Rare classifications.

Frequency-Classified Adverse Reactions

Reactions are most frequently observed across the general, endocrine, and gastrointestinal system-organ classes:

  • Very Common (ge 1/10): Reactions that are frequently observed include hot flush, breast tenderness, and gynecomastia (breast enlargement).
  • Common (ge 1/100 to <1/10): Reported effects include nausea, diarrhoea, constipation, asthenia (weakness), peripheral oedema, weight gain, and liver enzyme elevations.

Serious Safety Characteristics

Official labeling includes documentation of rare, but clinically significant, adverse reactions. These include serious effects on the hepatobiliary system, specifically hepatic failure, and serious reactions impacting the respiratory system, such as interstitial lung disease. Fatal outcomes have been reported in association with both conditions.

Population-Specific Notes and Constraints

Official documents define certain safety limitations. The medicine is contraindicated for use in individuals who are or may become pregnant. Additionally, caution is advised for use in patients with severe hepatic impairment due to observations of increased systemic exposure, while no specific dosage adjustment is typically required for individuals with renal impairment. The label also notes that liver enzyme elevations are generally reversible upon cessation of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory prescribing information for Bicalutamide (Biluron) does not formally establish the dose that results in symptoms of a life-threatening overdose. The official overdose profile, as defined by authorities like the FDA and EMA, is defined by the mandated emergency response and required supportive procedural management.

Immediate Emergency Action Required

Immediate medical help must be sought in all suspected cases of overdose. Emergency services must be contacted when severe, non-specific clinical signs are observed. These mandated triggers for urgent care include:

  • Collapse
  • Seizure
  • Trouble breathing
  • Inability to be awakened

The Poison Control Helpline should also be contacted for guidance as part of the initial emergency protocol.

Supportive Management

Treatment is explicitly mandated by regulators as symptomatic and general supportive care, as no specific antidote is known for Bicalutamide overdose. This approach is required because the drug does not have an established clinical toxicity profile. Supportive care officially indicated includes the frequent monitoring of vital signs and close observation of the patient by qualified medical personnel. Furthermore, the regulatory guidance notes that inducing vomiting may be considered as a procedural measure in the management of an acute overdose situation.

Therapeutic Uses of Biluron

What Biluron Treats: Main Uses and Benefits

Biluron (Bicalutamide) is a specialized hormonal therapy commonly used in adult male patients as part of the management of prostate cancer. The medication is applied in clinical situations where the disease is confirmed to be androgen-sensitive, meaning its progression is sensitive to hormonal influence. It is applied to help manage conditions where symptom manifestation is linked to hormonal factors.


Management of Advanced Disease

This domain covers Biluron's use in advanced stages of the disease, including locally advanced and metastatic carcinoma of the prostate. The medication is relevant for easing symptoms related to disease progression. This therapy supports management of symptoms related to hormone-driven tumor activity, which may be relevant for supporting a long-term treatment plan and contributes to easing the overall symptom load associated with advanced malignancy, such as cancer-associated pain.

Support in Contexts of Acute Symptom Fluctuation

Biluron is commonly used when patients are also receiving other supportive anti-hormonal care. A specific benefit it may assist with in this scenario is helping reduce the likelihood of a temporary spike in symptoms associated with treatment initiation. This supportive role may assist with maintaining functional stability and contributes to easing distress when initiating treatment, which supports the patient during difficult episodes of heightened discomfort.


Quick Fact: Relief for Hormone-Driven Discomfort

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile for Biluron (Bicalutamide)

Biluron is a medicine whose use is strictly defined by regulatory guidelines, restricting its eligibility to the population for whom it is indicated and establishing clear exclusions.

Eligibility Status Officially Documented Groups and Conditions
Absolute Contraindication Women (The medicine has no approved indication in females). Pregnancy and Lactation (Contraindicated due to risk of fetal harm). Children and Adolescents (Use is contraindicated, as safety and effectiveness are not established). Hypersensitivity (Contraindicated if allergic to Bicalutamide or any tablet component).
Required Caution Moderate to Severe Hepatic Impairment (Must be used with caution, as drug accumulation may occur due to slower elimination). QT Prolongation Risk (Caution advised in patients with existing risk factors). Excipient Intolerance (Use is not recommended for patients with rare hereditary problems of galactose intolerance or lactase deficiency).
Permitted Population Adult Male Patients (The approved group for the medicine's indication). Older Adults (No dosage adjustment is necessary based on age alone). Renal Impairment (No dosage adjustment is necessary for patients with impaired kidney function).

Official regulatory documents strictly define eligibility by confining its use exclusively to adult male patients with the approved indication. This is reinforced by absolute prohibitions that formally exclude women, children, and those with established allergies. Caution is mandated for patients with moderate to severe liver function compromise.

What should I know about interactions with other medicines?

Contraindicated Combinations

Co-administration of Biluron is officially prohibited with specific medicinal products. These combinations are classified as contraindicated due to the potential for the active R-enantiomer of Biluron to inhibit the CYP3A4 enzyme, which may lead to significantly increased systemic exposure of the co-administered drug. The prohibited co-administrations explicitly listed in regulatory documentation include Terfenadine, Astemizole, and Cisapride.


Drug-Drug Interaction Profile

The R-enantiomer is documented as a pharmacokinetic inhibitor of CYP3A4 and, to a lesser extent, CYP2C9, CYP2C19, and CYP2D6 activity. This necessitates caution with co-administered CYP3A4 substrates, particularly those with a narrow therapeutic index, as their plasma concentrations (AUC/Cmax) may be increased. Separately, Bicalutamide interacts pharmacodynamically with Coumarin Anticoagulants (such as Warfarin) through documented protein-binding displacement. This potentiation requires close monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR) to manage the potential for excessive prolongation. Caution is also advised regarding the concomitant use of drugs officially known to prolong the QT interval.


Other Interaction Conditions

The regulatory profile notes that co-administration with inhibitors of drug oxidation, such as Cimetidine or Ketoconazole, may theoretically increase Biluron concentrations. The drug may be taken with or without food, as no food-based interaction is documented. Caution is required in patients with severe hepatic impairment, as elimination of the active enantiomer may be delayed, potentially leading to increased systemic accumulation.

Mechanism of Action

Molecular Action: Competitive Blockade of the Androgen Receptor

Biluron's mechanism relies on the active (R)-enantiomer of Bicalutamide acting as a competitive antagonist to the Intracellular Androgen Receptor (AR) in target tissues. By physically occupying the receptor site, the drug prevents natural androgens (Testosterone and DHT) from binding and initiating signal transduction. . This molecular action establishes the compound as a pure anti-androgen, leading to the subsequent physiological effects.

Cellular Consequence: Inhibition of Androgen-Responsive Gene Expression

The physical blockade of the AR halts the typical signaling cascade, preventing the complex from translocating to the cell nucleus and initiating gene transcription. This suppression of androgen-responsive gene expression prevents the synthesis of proteins necessary for cell proliferation, resulting in growth arrest and regression of androgen-sensitive cells.

Systemic Effect: Disruption of the HPG Feedback Loop

The blockade of peripheral ARs disrupts the central Hypothalamic-Pituitary-Gonadal (HPG) axis feedback mechanism. This loss of negative feedback causes a compensatory increase in Luteinizing Hormone (LH) release from the pituitary gland, leading to a measurable elevation in systemic Testosterone concentrations. The mechanism's sustained action requires continuous high-affinity AR saturation to counteract the elevated compensatory hormone level.

Dosage and Administration Information

The administration of Biluron (Bicalutamide) is governed by specific protocols defining the dosage, frequency, and conditions of intake. The medicine is provided as a tablet intended exclusively for oral use.

Official Dosing Regimens

The treatment follows a once-daily schedule, though the required strength and the duration of therapy are contingent upon the prescribed treatment strategy.

Treatment Strategy Daily Dose & Schedule Duration/Context
Combination Therapy 50 mg once daily Used concomitantly with a Luteinizing Hormone-Releasing Hormone (LHRH) analog.
Monotherapy/Adjuvant 150 mg once daily Taken continuously for at least two years or until disease progression (dosage approval is regional).

Intake and Scheduling

Biluron should be taken at the same time each day for consistency, although the administration time can be either morning or evening. The tablet may be taken with or without food. When the 50 mg dose is initiated, its administration must start concurrently with the LHRH analog.

Procedural Rules and Adjustments

If a dose of Biluron is missed, the dose should be skipped entirely, and the next scheduled dose should be taken at the usual time; doubling the next dose is not permitted. Dosage adjustment is not necessary for adult patients with renal impairment or those with mild to moderate hepatic impairment. Use of this medication is not approved for the pediatric population. These established protocols provide a standardized approach to continuous daily use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biluron


Evidence for Management of Locally Advanced Prostate Cancer

Research examining Biluron's role in locally advanced, non-metastatic prostate cancer has been primarily conducted through large-scale, long-term Randomized Controlled Trials (RCTs). These studies were designed to compare outcomes in adult men receiving the medicine alongside standard care (such as radiation therapy) versus those receiving a placebo alongside standard care. Researchers examined long-term outcomes, including Overall Survival (OS) and how long patients remained free of disease progression.

Long-term follow-up analyses (some extending over 13 years) for specific RCTs reported that the group of patients with locally advanced disease who received the medicine alongside radiation demonstrated longer follow-up times compared to those receiving radiation and placebo. The research describes patterns observed in the studies, with data describing differences in the rate of distant metastasis during the study period. Findings for men with localized disease (T1–T2) managed by watchful waiting were mixed or inconclusive regarding this specific pattern.


Evidence for Management of Metastatic Carcinoma of the Prostate

The medicine was studied for use in adult men with Stage D2 metastatic carcinoma of the prostate. Many studies monitored its use as part of combined androgen blockade, meaning it was observed in combination with another hormonal treatment. Research examined how this combination compared to the hormonal treatment used alone, or how the medicine as a monotherapy compared to castration.

The Role of Biluron as a Comparator in Newer Research

In recent years, studies have frequently used this medicine as a standard treatment or comparator arm when testing newer-generation hormonal therapies. Research describes that these newer agents often reported different patterns related to progression-free survival (PFS) in advanced settings, such as Castration-Resistant Prostate Cancer (CRPC). This indicates that the role of Biluron continues to evolve as research is ongoing.


Evidence for Biochemical Recurrence (Rising PSA)

A significant amount of evidence comes from large RCTs that was observed in men who had experienced biochemical recurrence (a rising PSA level after initial treatment but with no visible sign of cancer spread). These trials monitored the effects on outcomes such as Overall Survival (OS) when the medicine was added to salvage radiation therapy (SRT).

Long-term follow-up data (with median observation periods extending past 10 years) from a major RCT reported that the group that received the medicine plus SRT demonstrated longer follow-up times compared to the group that received placebo plus SRT.

Key Studies & References

  1. FDA Label and Prescribing Information for Bicalutamide Tablets

Frequently Asked Questions (FAQ)

Common questions about Biluron (FAQ)

Q: How quickly does Biluron start to work after the first dose?

A: Because the active component of Biluron has a long half-life of about one week, it takes time to build up in the body. Official pharmacokinetic data indicates that the medicine usually reaches a stable, effective concentration (steady-state) in the bloodstream after continuous daily dosing for approximately 4 to 12 weeks.

Q: How long does Biluron remain in the patient's system after they stop taking it?

A: The active substance in Biluron has a plasma elimination half-life of approximately one week (7 to 10 days). Due to this long half-life, it takes several weeks after the final dose for the compound to be fully eliminated from the patient's system.

Q: What are the inactive and active ingredients in the Biluron formulation?

A: The active substance in Biluron is Bicalutamide. Regulatory documents also note that the tablets contain certain inactive ingredients, or excipients, such as lactose monohydrate. This is an important detail for patients who have known issues with certain types of sugar intolerance, such as lactose deficiency.

Q: Are there different strengths or formulations of Biluron available?

A: Biluron is formulated as an oral tablet. Official product information lists that the medicine is typically available in two different strengths, commonly 50 mg and 150 mg.

Q: Does Biluron interact with common over-the-counter pain relief medicines?

A: Official information notes that Biluron can affect an enzyme system called CYP3A4, which is involved in processing many other medicines. Caution is advised when taking any new medicine, including over-the-counter pain relievers, as this could potentially increase their concentration in the body. It is recommended that all combinations be reviewed by a healthcare professional.

Q: Is it acceptable to consume alcohol in small amounts while taking Biluron?

A: Official regulatory labels do not usually give specific advice about drinking alcohol in moderation while using the drug. However, caution is generally recommended with all medications, particularly because Biluron is associated with risks of liver toxicity.

Q: Has Biluron been associated with changes in sleep patterns?

A: Official safety information reports that Biluron may be associated with changes in sleep patterns. Both difficulty sleeping (insomnia) and increased drowsiness (somnolence) are listed as possible side effects.

Q: Is a feeling of mild dizziness or lightheadedness an expected effect of Biluron?

A: According to official safety information, dizziness and light-headedness are listed among the potential side effects of Biluron. Another related effect that has been reported is asthenia, which is a feeling of weakness or unusual tiredness.

Q: Do patients need to be cautious about operating machinery or driving while taking Biluron?

A: Official warnings advise patients to be cautious about operating machinery or driving while taking Biluron. This caution applies specifically if a patient experiences side effects such as drowsiness (somnolence) or dizziness, which can impair function.

Q: Does Biluron affect laboratory test results, such as blood pressure or blood sugar?

A: Official safety information indicates that Biluron can affect certain laboratory results. Reported effects include changes in blood sugar and blood pressure, and close monitoring of liver enzyme levels is often required during therapy. When Biluron is taken alongside blood thinners, the ability of the blood to clot must also be monitored closely.

Q: Are there official warnings against suddenly stopping the use of Biluron?

A: Regulatory warnings advise against stopping this medicine suddenly without medical guidance. In some patients whose disease has progressed, stopping the drug may trigger a reaction known as anti-androgen withdrawal syndrome. Any changes to the treatment plan must be discussed with the prescribing doctor.

Q: Does Biluron have any documented long-term safety concerns?

A: Official safety data documents rare but severe outcomes that have occurred with this medicine, including serious effects on the lungs (interstitial lung disease) and liver failure. Due to the possibility of liver changes, close monitoring of liver function is recommended during the first six months of treatment.

Q: Can Biluron affect fertility in men or women?

A: Regulatory documents state that Biluron is strictly contraindicated for use in females. In adult male patients, studies have shown that the drug may cause reversible impairment of fertility. Official information suggests that a period of subfertility or infertility may be possible while on treatment.

Q: Is Biluron known to have any effect on a patient's mood or emotional state?

A: As a hormonal therapy, Biluron has been reported to affect a patient's emotional state. Official safety sources list mood changes, including feelings of depression or feeling low, as possible side effects.

Q: Does Biluron cause any changes in appetite?

A: Official patient information reports that loss of appetite, clinically known as anorexia, is listed as a potential side effect of the medication.

Q: What should a patient do if they accidentally take more Biluron than prescribed?

A: Official prescribing information notes that there is no known specific antidote or reversal agent available for an accidental overdose of Biluron. In such cases, the reported approach involves general supportive medical care and closely monitoring the patient’s vital signs.

Q: Is there a known antidote or reversal agent for Biluron?

A: Official prescribing information states clearly that there is no known specific antidote or reversal agent for Biluron. Official information suggests that any management would focus on general supportive care.

How should Biluron be stored and disposed of?

Official Storage and Disposal Requirements for Biluron

The regulatory labeling for Biluron specifies strict conditions to maintain product stability and safety. The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is mandatory to keep the product in its original, tightly closed container, protected from both excessive heat (do not store above 30 C) and moisture and light.

Handling and Stability:

  • Do not freeze the medicine.
  • If applicable, a Beyond-Use Date (BUD) may require discarding the product, for instance, 28 days after first opening.

Disposal and Safety:

Official instructions require that Biluron be stored out of the sight and reach of children.

For disposal, do not flush Biluron down a toilet or pour it into a drain. Expired or unused medicine must be returned to a designated medicine take-back location or pharmacy to prevent environmental contamination, as instructed by governmental disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biluron found in:

A-Z Index: